https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Front Oncol 2020;10:187
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Front Oncol 2020;10:1872020-02-21 00:00:002020-02-21 00:00:00Immunotherapy in Malignant Pleural Mesothelioma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-77
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-21 / Magy Onkol 2021 Mar;65(1):71-772020-02-21 00:00:002020-02-21 00:00:00[The adjuvant killing effect of modulated electro-hyperthermia combined with chemotherapy on B16F10 melanoma cells]
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-1387
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-20 / Cancer Immunol. Immunother. 2020 Jul;69(7):1375-13872020-02-20 00:00:002020-02-20 00:00:00Tumor-associated antigen-based personalized dendritic cell vaccine in solid tumor patients
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-09 / Neoplasma 2020 May;67(3):677-683
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-09 / Neoplasma 2020 May;67(3):677-6832020-02-09 00:00:002020-02-09 00:00:00Feasibility of modulated electro-hyperthermia in preoperative treatment for locally advanced rectal cancer: Early phase 2 clinical results
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-07 / J Clin Oncol 38, 2020 (suppl 5; abstr 63)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-07 / J Clin Oncol 38, 2020 (suppl 5; abstr 63)2020-02-07 00:00:002020-08-31 08:23:53Multi-institutional, prospective, randomized, double-blind, placebo-controlled phase IIb trial of the tumor lysate, particle-loaded, dendritic cell (TLPLDC) vaccine to prevent recurrence in high-risk melanoma patients: A subgroup analysis.
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e18889
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / Medicine (Baltimore) 2020 Feb;99(8):e188892020-02-01 00:00:002020-02-01 00:00:00Substantial tumor regression in prostate cancer patient with extensive skeletal metastases upon Immunotherapy (APCEDEN): A case report
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S119
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / Transl Lung Cancer Res 2020 Feb;9(Suppl 1):S100-S1192020-02-01 00:00:002020-12-09 09:48:40Immunotherapy for mesothelioma: a critical review of current clinical trials and future perspectives
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-02-01 / J Immunother Cancer 2020 02;8(1)
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-02-01 / J Immunother Cancer 2020 02;8(1)2020-02-01 00:00:002020-02-01 00:00:00TriMix and tumor antigen mRNA electroporated dendritic cell vaccination plus ipilimumab: link between T-cell activation and clinical responses in advanced melanoma
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-31 / Biomed. Pharmacother. 2020 May;125:109966
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-31 / Biomed. Pharmacother. 2020 May;125:1099662020-01-31 00:00:002020-01-31 00:00:00Interferon-α2b enhances survival and modulates transcriptional profiles and the immune response in melanoma patients treated with dendritic cell vaccines
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
0
0
2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-262
https://www.iozk.de/wp-content/uploads/2019/03/Logo-header560x120.svg
2020-01-27 / Expert Opin Biol Ther 2020 03;20(3):253-2622020-01-27 00:00:002020-01-27 00:00:00Novel immunotherapy combinations for genitourinary cancers
